Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.
Planning to file anti-CD38 agent felzartamab for approval in third-line multiple myeloma before the end of 2021, Shanghai-based I-Mab Biopharma Co., Ltd said it will transition into a commercial biopharma with the help of Sinopharm Group Co. Ltd
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?